SCHEMBL985500

SCHEMBL985500

Cc1cc(C(=O)Cl)cc(C)c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.36
MGAM O43451 1/20 0.36
AMY1A P0DUB6 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
HDAC1 Q13547 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
HTT P42858 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
TPMT P51580 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22490311 0.86 TTR (0.35) GAAKMT2AKDM4EMEN1KCNQ3
SCHEMBL2155225 0.84 TTR (0.36) KMT2AMEN1KCNQ3KCNQ2SMN1; SMN2
SCHEMBL11807871 0.82 CA1 (0.48) KMT2AKDM4EMEN1SMN1; SMN2HTT
SCHEMBL2154502 0.82 ALDH1A1 (0.38) KMT2AMEN1KCNQ3KCNQ2SMN1; SMN2
SCHEMBL17946064 0.81 MEN1 (0.47) KMT2AMEN1HTTTPMTALDH1A1
SCHEMBL16338726 0.80 CES2 (0.36) HDAC1HDAC6KMT2AKCNQ3KCNQ2
SCHEMBL16384672 0.80 TPMT (0.34) KMT2AMEN1KCNQ3KCNQ2SMN1; SMN2
SCHEMBL11762810 0.78 PKM (0.39) GAAKDM4EALDH1A1
SCHEMBL12399061 0.78 SMN1; SMN2 (0.46) GAAMGAMAMY1ASIMGAM2
Ethane SCHEMBL29138437 0.77 ALDH1A1 (0.37) HDAC6HDAC8TPMTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288652-B1 PREPARATION FOR INITIATING RADICAL REACTIONS UNITED INITIATORS GMBH & CO KG (DE) 2012-09-19 EP claimed
US-20110272628-A1 Preparation For Initiating Radical Reactions UNITED INITIATORS GMBH (DE) 2011-11-10 US claimed
EP-2288652-A1 PREPARATION FOR INITIATING RADICAL REACTIONS United Initiators GmbH & Co. KG (DE) 2011-03-02 EP claimed
WO-2009146916-A1 PREPARATION FOR INITIATING RADICAL REACTIONS UNITED INITIATORS GMBH & CO. KG (DE) 2009-12-10 WO claimed
EP-2130858-A1 Preparations to initiate radical reactions Degussa Initiators GmbH & Co. KG (DE) 2009-12-09 EP claimed
CN-113999126-B Preparation method of trimebutine 浙江东亚药业股份有限公司 2024-05-24 CN disclosed
CN-114014824-B Application of heterocyclic compound 上海科技大学 2023-06-13 CN disclosed
CN-114014824-A Application of heterocyclic compound 上海科技大学 2022-02-08 CN disclosed
CN-113999126-A Preparation method of trimebutine 浙江东亚药业股份有限公司 2022-02-01 CN disclosed
US-20180002709-A1 RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-01-04 US disclosed
US-9682931-B2 Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof UBE INDUSTRIES, LTD. (JP) 2017-06-20 US disclosed
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF UBE INDUSTRIES, LTD. (JP) 2016-08-25 US disclosed
US-7875631-B2 e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed ANALYTECON S.A. (CH) 2011-01-25 US disclosed
WO-2009146916-A1 PREPARATION FOR INITIATING RADICAL REACTIONS UNITED INITIATORS GMBH & CO. KG (DE) 2009-12-10 WO disclosed
EP-2130858-A1 Preparations to initiate radical reactions Degussa Initiators GmbH & Co. KG (DE) 2009-12-09 EP disclosed
US-7528212-B2 Ionizing radiation stable thermoplastic composition, method of making, and articles formed therefrom SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-05-05 US disclosed
US-20070117957-A1 Ionizing radiation stable thermoplastic composition, method of making, and articles formed therefrom SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2007-05-24 US disclosed
US-4585866-A Treatment of migraine with substituted tropyl benzoate derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1986-04-29 US disclosed
US-4563465-A ANTISEROTONINE AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1986-01-07 US disclosed
US-4001426-A HAVING CORONARY VASODILATOR ACTIVITY SMITHKLINE CORPORATION (US) 1977-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002709-A1 RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS NPEPPS, DNPEP, AARS1 GAA 2131/4885MGAM 873/4885AMY1A 4030/4885
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF SLCO1B1, SLCO2B1, SLCO1B3 GAA 1056/4885MGAM 1479/4885AMY1A 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.